Abstract
C21H19ClO3, orthorhombic, P212121 (no. 19), a = 6.0384(3) Å, b = 11.5696(7) Å, c = 24.6624(14) Å, V = 1722.96(17) Å3, Z = 4, Rgt(F) = 0.0253, wRref(F2) = 0.0637, T = 100(2) K.
Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Data collection and handling.
| Crystal: | Colourless block |
| Size: | 0.12 × 0.11 × 0.10 mm |
| Wavelength: | Mo Kα radiation (0.71073 Å) |
| μ: | 0.24 mm−1 |
| Diffractometer, scan mode: | Bruker APEX-II, φ and ω |
| θmax, completeness: | 27.5°, >99 % |
| N(hkl)measured, N(hkl)unique, Rint: | 38,454, 3,941, 0.034 |
| Criterion for Iobs, N(hkl)gt: | Iobs > 2σ(Iobs), 3,775 |
| N(param)refined: | 228 |
| Programs: | Bruker, 1 Olex2, 2 SHELX 3 |
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).
| Atom | x | y | z | Uiso*/Ueq |
|---|---|---|---|---|
| C1 | 0.2270 (3) | 1.04625 (15) | 0.28766 (7) | 0.0194 (3) |
| C2 | 0.4274 (3) | 1.07362 (15) | 0.31135 (7) | 0.0219 (3) |
| H2 | 0.484060 | 1.150126 | 0.309559 | 0.026* |
| C3 | 0.5447 (3) | 0.98697 (15) | 0.33790 (7) | 0.0210 (4) |
| H3 | 0.683023 | 1.004660 | 0.354244 | 0.025* |
| C4 | 0.4622 (3) | 0.87454 (14) | 0.34089 (7) | 0.0182 (3) |
| C5 | 0.2588 (3) | 0.84995 (15) | 0.31706 (7) | 0.0204 (3) |
| H5 | 0.200330 | 0.773837 | 0.319115 | 0.024* |
| C6 | 0.1400 (3) | 0.93574 (15) | 0.29025 (7) | 0.0211 (3) |
| H6 | 0.001262 | 0.918682 | 0.273954 | 0.025* |
| C7 | 0.5979 (3) | 0.78552 (14) | 0.37062 (7) | 0.0222 (4) |
| H7A | 0.749753 | 0.783092 | 0.355496 | 0.027* |
| H7B | 0.608188 | 0.806236 | 0.409483 | 0.027* |
| C8 | 0.6135 (3) | 0.58359 (15) | 0.38336 (7) | 0.0187 (3) |
| C9 | 0.4817 (3) | 0.47210 (15) | 0.37716 (7) | 0.0183 (3) |
| H9 | 0.349528 | 0.478680 | 0.401387 | 0.022* |
| C10 | 0.3945 (3) | 0.45619 (15) | 0.31906 (7) | 0.0221 (4) |
| H10A | 0.306956 | 0.523964 | 0.308637 | 0.033* |
| H10B | 0.301269 | 0.386944 | 0.317409 | 0.033* |
| H10C | 0.519693 | 0.447512 | 0.294101 | 0.033* |
| C11 | 0.6108 (3) | 0.36680 (14) | 0.39559 (6) | 0.0175 (3) |
| C12 | 0.5192 (3) | 0.29156 (14) | 0.43216 (7) | 0.0160 (3) |
| H12 | 0.378630 | 0.308901 | 0.447406 | 0.019* |
| C13 | 0.6289 (3) | 0.18849 (14) | 0.44783 (6) | 0.0145 (3) |
| C14 | 0.8407 (3) | 0.16267 (14) | 0.42529 (6) | 0.0141 (3) |
| C15 | 0.9335 (3) | 0.24205 (14) | 0.38758 (6) | 0.0165 (3) |
| H15 | 1.074708 | 0.226613 | 0.372226 | 0.020* |
| C16 | 0.8222 (3) | 0.34038 (15) | 0.37310 (7) | 0.0189 (3) |
| H16 | 0.886945 | 0.391880 | 0.347634 | 0.023* |
| C17 | 0.5342 (3) | 0.10947 (14) | 0.48533 (7) | 0.0160 (3) |
| H17 | 0.393761 | 0.125906 | 0.500866 | 0.019* |
| C18 | 0.6424 (3) | 0.01022 (14) | 0.49937 (7) | 0.0162 (3) |
| H18 | 0.577241 | −0.041597 | 0.524638 | 0.019* |
| C19 | 0.8519 (3) | −0.01570 (14) | 0.47628 (7) | 0.0157 (3) |
| C20 | 0.9503 (3) | 0.05846 (13) | 0.44007 (6) | 0.0145 (3) |
| H20 | 1.090792 | 0.040274 | 0.424983 | 0.017* |
| C21 | 1.1330 (3) | −0.15936 (16) | 0.46643 (7) | 0.0224 (4) |
| H21A | 1.100377 | −0.169301 | 0.427786 | 0.034* |
| H21B | 1.177810 | −0.233706 | 0.481993 | 0.034* |
| H21C | 1.253368 | −0.103295 | 0.470783 | 0.034* |
| Cl1 | 0.08243 (8) | 1.15281 (4) | 0.25211 (2) | 0.02824 (12) |
| O1 | 0.4944 (2) | 0.67421 (10) | 0.36484 (5) | 0.0217 (3) |
| O2 | 0.7957 (2) | 0.59384 (11) | 0.40253 (6) | 0.0258 (3) |
| O3 | 0.9393 (2) | −0.11810 (10) | 0.49381 (5) | 0.0199 (3) |
1 Source of material
The compound was obtained commercially (Bide Pharmatech Co., Ltd). Crystals suitable for the diffraction study were taken directly from the provided product.
2 Experimental details
Coordinates of hydrogen atoms were constrained by some AFIX 3 options. The Uiso values were set to be 1.5Ueq of the carrier atom for methyl and 1.2Ueq for remaining H atoms.
3 Comment
Naproxen, a potent non-steroidal anti-inflammatory drug (NSAID), blocks the activity of both COX-1 and COX-2 enzymes, which are key components of the cyclooxygenase pathway. Naproxen commonly causes gastrointestinal reactions, such as gastrointestinal bleeding. 1 These side effects may be linked to the carboxyl group present in naproxen. Esterifying the carboxyl group has been shown to reduce these side effects. 2 , 3 Currently, naproxen is used clinically to treat or alleviate inflammation and pain caused by various conditions such as rheumatoid arthritis 4 and gout. 5 Additionally, naproxen has been found to exhibit many interesting applications. 6 , 7 , 8 Therefore, the development of naproxen derivatives with fewer side effects is of significant importance.
The title compound contains one naphthyl ring and one phenyl ring. The bond distances of C–O are 1.439(2) Å (C7–O1), 1.204(2) Å (C8–O2),1.3671(19) Å (C19–O3), 1.432(2) Å (C21–O3) and 1.351(2) Å (C8–O1). The bond distance of C8–O2 are shorter than others, indicating a double bond. The bond of C–Cl is 1.7466(17) Å (C1–Cl1). The dihedral angels of ring 1 (C1–C2–C3–C4–C5–C6) and ring 2 (C11–C12–C13–C14–C15–C16), ring 1 (C1–C2–C3–C4–C5–C6) and ring 3 (C14–C13–C17–C18–C19–C20), and ring 2 (C11–C12–C13–C14–C15–C16) and ring 3 (C14–C13–C17–C18–C19–C20) are 58.82(7)°, 56.88(7)° and 0.90(6)°. The other bond distances and angles are in their normal ranges according to the previously reported compounds. 9 , 10
-
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
-
Conflict of interest statement: The authors declare no conflicts of interest regarding this article.
References
1. Bruker. SAINT and SADABS; Bruker AXS Inc.: Madison, Wisconsin, USA, 2000.Suche in Google Scholar
2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar
3. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar
4. Huang, Z. J.; Carlos, A. V.; Khaled, R. A. A.; Morshed, A. C.; Julie, A. R.; Jenna, F. D.; Bruce King, S.; Edward, E. K. Ethanesulfohydroxamic Acid Ester Prodrugs of Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Synthesis, Nitric Oxide and Nitroxyl Release, Cyclooxygenase Inhibition, Anti-inflammatory, and Ulcerogenicity Index Studies. J. Med. Chem. 2011, 54, 1356–1364; https://doi.org/10.1021/jm101403g.Suche in Google Scholar PubMed
5. Han, M. I.; Kucukguzel, S. G. Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives. Mini Rev. Med. Chem. 2020, 20, 1300–1310; https://doi.org/10.2174/1389557520666200505124922.Suche in Google Scholar PubMed
6. Srinivas, S.; Feldman, D. A Phase II Trial of Calcitriol and Naproxen in Recurrent Porstate Cancer. Anticancer Res. 2009, 29, 3605–3610.Suche in Google Scholar
7. Kim, M. S.; Kim, J. E.; Lim, D. Y.; Huang, Z.; Chen, H.; Langfald, A.; Lubet, R. A.; Grubbs, C. J.; Dong, Z.; Bode, A. M. Naproxen Induces Cell Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting P13–K. Canc. Prev. Res. 2014, 7, 236–245; https://doi.org/10.1158/1940-6207.capr-13-0288.Suche in Google Scholar PubMed PubMed Central
8. Liang, D.; Yang, X. H.; Sun, W.; Wang, W. N.; Yang, J. Z.; Liu, Y. Y.; Wang, G. S. Synthesis Crystal Structure and Biological Activities of Naproxen-Eugenol Ester Progrug. Chem. Res. Chinese Univ. 2013, 29, 245–248; https://doi.org/10.1007/s40242-013-2266-9.Suche in Google Scholar
9. Wang, L. L.; Xue, D. D. Crystal Structure of 3-phenylpropyl 2-(6-Methoxynaphthalen-2-Yl)propanpate, C23H24O3. Z. Kristallogr. N. Cryst. Struct. 2022, 237, 517–519; https://doi.org/10.1515/ncrs-2022-0114.Suche in Google Scholar
10. Wang, L.; Lu, W.; Zhang, J.; Chong, Q.; Meng, F. Cobalt-Catalyzed Regio-Diastereo- and Enantioselective Intermolecular Hydrosilylation of 1,3-Dienes with Prochiral Silanes. Angew. Chem. Int. Ed. 2022, 61, e202205624; https://doi.org/10.1002/anie.202205624.Suche in Google Scholar PubMed
© 2024 the author(s), published by De Gruyter, Berlin/Boston
This work is licensed under the Creative Commons Attribution 4.0 International License.
Artikel in diesem Heft
- Frontmatter
- Editorial
- Editorial 2024 – New developments and changes of Zeitschrift für Kristallographie – New Crystal Structures
- New Crystal Structures
- Hydrogen bonding and π⋅⋅⋅halogen interactions in the crystal structure of bis(theophyllinium) hexachloridoplatinate(IV) monohydrate
- The crystal structure of 6-amino-2-carboxypyridin-1-ium perchlorate, C6H7ClN2O6
- Crystal structure of poly[(μ4-(3-amino-1H-1,2,4-triazol-1-yl)benzene-1,3-dicarboxylato-κ 4 N:O:O':O')(1-methylpyrroldin-2-one-κ1O)dicopper(II)] – 1-methylpyrroldin-2-one (1/3), C40H48Cu2N12O12
- The crystal structure of 18-crown-6-k6O6(2,4,5-trinitroimidazol-1-ido-k1O)potassium(I)
- Crystal structure of poly[tetraaqua-bis(μ2-5-bromoisophthalato-κ3O,O′:O″)-(μ2-1,5-bis(imidazol-2-methyl)pentane-κ2N:N′)dicadmium(II)] dihydrate
- Crystal structure of (5R,6S,E)-5-acetoxy-2-methyl-6-((2aR,3R,5aS,5bS,11aR,12aS)-2a,5a,8,8-tetramethyl-9-oxotetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-3-yl)hept-2-enoic acid, C32H48O5
- The crystal structure of poly[diaqua-bis(μ2 -thiocyanato-κ2N:O)cobalt(II) monohydrate
- The crystal structure of 1,3,5-tri(1H-imidazol-1-yl)benzene–2,3,5,6-tetrachlorobenzene-1,4-dicarboxylic acid (1/1)
- Crystal structure of dichlorido-bis(1-[(2-ethyl-benzimidazole-1-yl)methyl]-1H–benzotriazole) cadmium(II), C32H32CdN10OCl2
- The crystal structure of N′-(tert-butyl)-N′-(3,5-dimethylbenzoyl)-3-methoxy-N,2-dimethylbenzohydrazide, C23H30N2O3
- Crystal stucture of 3-benzamido-N-(2-bromo-4-(perfluoropropan-2-yl)-6-(trifluoromethyl)phenyl)-2-fluorobenzamide
- Crystal structure of bis(μ-benzeneselenolato)-(tetracarbonyl)-{μ-[N-(diphenylphosphanyl)-N-(3-ethynylphenyl)-P,P-diphenylphosphinous amide]} diiron, C48H35Fe2NO4P2Se2
- The crystal structure of 2′-(p-tolyl)-4′H-spiro[isochromane-1,1′-naphthalene]-3,4′-dione, C25H18O3
- The crystal structure of poly[hexaqua-tetrakis(μ4-pyridine-2,4-dicarboxylate-κ5N: O: O′: O″: O‴)-bi(μ2-pyridine-2,4-dicarboxylate-κ3N: O: O′)-digadolinium(III)tricopper (II)], [Gd2Cu3(C7H3NO4)6(H2O)6] n
- Crystal structure of poly[bis(4-(4-(pyridin-4-yl)phenyl)pyridin-1-ium-κ1N)-(μ4-benzene-1,2,4,5-tetracarboxylato-κ5O:O′: O″:O‴:O⁗)-(μ2-2,5-dicarboxyterephthalato-κ2O:O′)dizinc(II)], C52H32N4O16Zn2
- The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 2-carboxy-6-nitrobenzoate monohydrate, C24H25FN4O10
- Crystal structure of dichlorido-(1-((3,5-dimethyl-2,3-dihydro-1H-1,2,3-triazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-k1N)zinc(II), C22H24ZnN12Cl2
- The crystal structure of (3-chlorothiophene-2-carboxylato-κ2O, O′)-(2,2′-dipyridyl-κ2N,N′)lead(II), C20H12Cl2N2O4S2Pb
- Synthesis and crystal structure of (Z)-4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methylene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one, C19H14FN5O
- The crystal structure of the coordination compound catena-poly[(18-crown-6-ether-κ6O6)(4,5-dinitroimidazolato-κ1O)potassium(I)]
- Crystal structure of 7-(diethylamino)-3-(trifluoroacetyl)-2H-chromen-2-one, C15H14F3NO3
- Crystal structure of dichlorido-1-[(2-ethylimidazole-1-yl)methyl]-1H–benzotriazole κ1N zinc(II), C24H26ZnN10Cl2
- Crystal and molecular structure of 5-bromopyridine-2,3-diamine
- Crystal structure of catena-poly[bis(μ2-1-(3-carboxyphenyl)-5-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylato-k3-O,O′:O″)hexaqua-dicobalt tetrahydrate], C26H36N4O20Co2
- Crystal structure of thiocyanate-κ1N-bis(μ1-2,6-diformyl-4-methylphenol oxime-κ2N,O)-manganese(III) acetonitrile solvate, C21H21MnN6O6S
- The crystal structure of pyrrolidin-1-yl pivalate, C9H13NO4
- The crystal structure of 2,2′-(2,2-diphenylethene-1,1-diyl)bis(1,4-dimethoxybenzene), C30H28O4
- Crystal structure of bis(benzyltrimethylammonium) tetrathiotungstate(VI), {(C6H5CH2)(CH3)3N}2[WS4]
- The crystal structure of ethyl (Z)-2-(ethoxymethylene)-3-oxobutanoate, C9H14O4
- The crystal structure of (E)-6-bromo-3,5-dimethyl-2-(1-phenylprop-1-en-2-yl)-3Himidazo[4,5b]pyridine, C17H16BrN3
- Crystal structure of (3S,3′S,4R,4′S)-3′-(furan-3-yl)-3-hydroxy-4′-methyl-3,5,6′,7′-tetrahydro-1H,3′H-4,5′-spirobi[isobenzofuran]-1,1′(4′H)-dione-methanol (1/1), C21H22O7
- Cocrystal structure of progesterone-isophthalic acid, C25H33O4
- The crystal structure of 3-(6-fluoro-1H-indol-3-yl)-1-methylquinoxalin-2(1H)-one, C17H12FN3O
- Crystal structure of S-(4-carboxybutyl)- l -cysteine
- The cocrystal of 2,2′-(hydrazine-1,1-diyl)bis(1H-imidazole-4,5-dicarbonitrile)– methanol (2/3)
- Crystal structure of (1′R,2′S,4′R,6′S)-4,6-dihydroxy-1′,8′,8′-trimethyl-3-(3-methylbutanoyl)-4′,8′,6′,1′,7,2′-hexahydro-1H-4′,6′-methanoxanthene-8-carbaldehyde, C23H30O5
- Crystal structure of (3,6-di(2-pyridyl)-4-methylphenyl pyridazine-k 2 N,N′)-bis(1-phenyl-pyrazole-κ 2 C,N) iridium(III) hexafluorophosphate, C39H29F6IrN8P
- Crystal structure of 1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene]thiocarbonohydrazide dimethyl sulfoxide monosolvate, C17H18N4O2S·C2H6OS
- Crystal structure of (S)-4-(2-(4-(2-acetyl-5-chlorophenyl)-3-methoxy-6-oxopyridazin-1(6H)-yl)-3-phenylpropanamido)benzoic acid monohydrate, C29H26ClN3O7
- The crystal structure of 1,3-bis(2,4-dinitro-1H-imidazol-1-yl)propane
- Crystal structure of 4-chlorobenzyl (S)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H19ClO3
- Crystal structure of 1-(5-(benzo[d][1,3]dioxol-5-yl)-4-benzyl-1-(4-bromophenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)ethan-1-one, C24H20BrN3O3
- The crystal structure of (Z)-3′-(2-(1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazinyl)-2′-hydroxy-[1,1′-biphenyl]-3-carboxylicacid ─ methanol (1/1), C26H26N4O5
- Crystal structure of (S)-1-phenylpropan-1-aminium (S)-(1-phenylpropyl)carbamate C19H26N2O2
- Synthesis and crystal structure of methyl 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate, C18H16BrN3O2S
- The crystal structure of trichlorobis(pyridine-2,6-dithio-κS-carbomethylamido)antimony(III), [SbCl3(C9H11N3S2)2]
- Crystal structure of 1,8-dihydroxy-3-{[(triphenylstannyl)oxy]carbonyl} anthracene-9,10-dione, C33H22O6Sn
- The crystal structure of (E)-4-(2-(pyridin-4-ylmethylene)hydrazine-1-carbonyl)pyridin-1-ium-2-olate dihydrate, C12H14N4O4
- The crystal structure of 6-amino-pyridinium-2-carboxylate, C6H6N2O2
- The crystal structure of catena-poly[aqua-nitrato-κ3O,O:O′′-(1,10-phenanthroline-κ2N,N′)sodium(I)], C24H18N6O7Na2
- Retractions
- Retraction of: Crystal structure of bis[diaquaisonicotinatosamarium(III)]-µ-isonicotinato-[diisonicotinatocopper(II)], CuSm2(C6H4NO2)8(H2O)4
- Retraction of: Crystal structure of aqua(2,2′-bipyridine-k 2 N:N′)(nitrato)-(4-aminobenzoato)cadmium(II) nitrate, [Cd(H2O)(NO3)(C10H8N2)(C7H7NO2)][NO3]
Artikel in diesem Heft
- Frontmatter
- Editorial
- Editorial 2024 – New developments and changes of Zeitschrift für Kristallographie – New Crystal Structures
- New Crystal Structures
- Hydrogen bonding and π⋅⋅⋅halogen interactions in the crystal structure of bis(theophyllinium) hexachloridoplatinate(IV) monohydrate
- The crystal structure of 6-amino-2-carboxypyridin-1-ium perchlorate, C6H7ClN2O6
- Crystal structure of poly[(μ4-(3-amino-1H-1,2,4-triazol-1-yl)benzene-1,3-dicarboxylato-κ 4 N:O:O':O')(1-methylpyrroldin-2-one-κ1O)dicopper(II)] – 1-methylpyrroldin-2-one (1/3), C40H48Cu2N12O12
- The crystal structure of 18-crown-6-k6O6(2,4,5-trinitroimidazol-1-ido-k1O)potassium(I)
- Crystal structure of poly[tetraaqua-bis(μ2-5-bromoisophthalato-κ3O,O′:O″)-(μ2-1,5-bis(imidazol-2-methyl)pentane-κ2N:N′)dicadmium(II)] dihydrate
- Crystal structure of (5R,6S,E)-5-acetoxy-2-methyl-6-((2aR,3R,5aS,5bS,11aR,12aS)-2a,5a,8,8-tetramethyl-9-oxotetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-3-yl)hept-2-enoic acid, C32H48O5
- The crystal structure of poly[diaqua-bis(μ2 -thiocyanato-κ2N:O)cobalt(II) monohydrate
- The crystal structure of 1,3,5-tri(1H-imidazol-1-yl)benzene–2,3,5,6-tetrachlorobenzene-1,4-dicarboxylic acid (1/1)
- Crystal structure of dichlorido-bis(1-[(2-ethyl-benzimidazole-1-yl)methyl]-1H–benzotriazole) cadmium(II), C32H32CdN10OCl2
- The crystal structure of N′-(tert-butyl)-N′-(3,5-dimethylbenzoyl)-3-methoxy-N,2-dimethylbenzohydrazide, C23H30N2O3
- Crystal stucture of 3-benzamido-N-(2-bromo-4-(perfluoropropan-2-yl)-6-(trifluoromethyl)phenyl)-2-fluorobenzamide
- Crystal structure of bis(μ-benzeneselenolato)-(tetracarbonyl)-{μ-[N-(diphenylphosphanyl)-N-(3-ethynylphenyl)-P,P-diphenylphosphinous amide]} diiron, C48H35Fe2NO4P2Se2
- The crystal structure of 2′-(p-tolyl)-4′H-spiro[isochromane-1,1′-naphthalene]-3,4′-dione, C25H18O3
- The crystal structure of poly[hexaqua-tetrakis(μ4-pyridine-2,4-dicarboxylate-κ5N: O: O′: O″: O‴)-bi(μ2-pyridine-2,4-dicarboxylate-κ3N: O: O′)-digadolinium(III)tricopper (II)], [Gd2Cu3(C7H3NO4)6(H2O)6] n
- Crystal structure of poly[bis(4-(4-(pyridin-4-yl)phenyl)pyridin-1-ium-κ1N)-(μ4-benzene-1,2,4,5-tetracarboxylato-κ5O:O′: O″:O‴:O⁗)-(μ2-2,5-dicarboxyterephthalato-κ2O:O′)dizinc(II)], C52H32N4O16Zn2
- The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 2-carboxy-6-nitrobenzoate monohydrate, C24H25FN4O10
- Crystal structure of dichlorido-(1-((3,5-dimethyl-2,3-dihydro-1H-1,2,3-triazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-k1N)zinc(II), C22H24ZnN12Cl2
- The crystal structure of (3-chlorothiophene-2-carboxylato-κ2O, O′)-(2,2′-dipyridyl-κ2N,N′)lead(II), C20H12Cl2N2O4S2Pb
- Synthesis and crystal structure of (Z)-4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methylene)-5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one, C19H14FN5O
- The crystal structure of the coordination compound catena-poly[(18-crown-6-ether-κ6O6)(4,5-dinitroimidazolato-κ1O)potassium(I)]
- Crystal structure of 7-(diethylamino)-3-(trifluoroacetyl)-2H-chromen-2-one, C15H14F3NO3
- Crystal structure of dichlorido-1-[(2-ethylimidazole-1-yl)methyl]-1H–benzotriazole κ1N zinc(II), C24H26ZnN10Cl2
- Crystal and molecular structure of 5-bromopyridine-2,3-diamine
- Crystal structure of catena-poly[bis(μ2-1-(3-carboxyphenyl)-5-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylato-k3-O,O′:O″)hexaqua-dicobalt tetrahydrate], C26H36N4O20Co2
- Crystal structure of thiocyanate-κ1N-bis(μ1-2,6-diformyl-4-methylphenol oxime-κ2N,O)-manganese(III) acetonitrile solvate, C21H21MnN6O6S
- The crystal structure of pyrrolidin-1-yl pivalate, C9H13NO4
- The crystal structure of 2,2′-(2,2-diphenylethene-1,1-diyl)bis(1,4-dimethoxybenzene), C30H28O4
- Crystal structure of bis(benzyltrimethylammonium) tetrathiotungstate(VI), {(C6H5CH2)(CH3)3N}2[WS4]
- The crystal structure of ethyl (Z)-2-(ethoxymethylene)-3-oxobutanoate, C9H14O4
- The crystal structure of (E)-6-bromo-3,5-dimethyl-2-(1-phenylprop-1-en-2-yl)-3Himidazo[4,5b]pyridine, C17H16BrN3
- Crystal structure of (3S,3′S,4R,4′S)-3′-(furan-3-yl)-3-hydroxy-4′-methyl-3,5,6′,7′-tetrahydro-1H,3′H-4,5′-spirobi[isobenzofuran]-1,1′(4′H)-dione-methanol (1/1), C21H22O7
- Cocrystal structure of progesterone-isophthalic acid, C25H33O4
- The crystal structure of 3-(6-fluoro-1H-indol-3-yl)-1-methylquinoxalin-2(1H)-one, C17H12FN3O
- Crystal structure of S-(4-carboxybutyl)- l -cysteine
- The cocrystal of 2,2′-(hydrazine-1,1-diyl)bis(1H-imidazole-4,5-dicarbonitrile)– methanol (2/3)
- Crystal structure of (1′R,2′S,4′R,6′S)-4,6-dihydroxy-1′,8′,8′-trimethyl-3-(3-methylbutanoyl)-4′,8′,6′,1′,7,2′-hexahydro-1H-4′,6′-methanoxanthene-8-carbaldehyde, C23H30O5
- Crystal structure of (3,6-di(2-pyridyl)-4-methylphenyl pyridazine-k 2 N,N′)-bis(1-phenyl-pyrazole-κ 2 C,N) iridium(III) hexafluorophosphate, C39H29F6IrN8P
- Crystal structure of 1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene]thiocarbonohydrazide dimethyl sulfoxide monosolvate, C17H18N4O2S·C2H6OS
- Crystal structure of (S)-4-(2-(4-(2-acetyl-5-chlorophenyl)-3-methoxy-6-oxopyridazin-1(6H)-yl)-3-phenylpropanamido)benzoic acid monohydrate, C29H26ClN3O7
- The crystal structure of 1,3-bis(2,4-dinitro-1H-imidazol-1-yl)propane
- Crystal structure of 4-chlorobenzyl (S)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H19ClO3
- Crystal structure of 1-(5-(benzo[d][1,3]dioxol-5-yl)-4-benzyl-1-(4-bromophenyl)-4,5-dihydro-1H-1,2,4-triazol-3-yl)ethan-1-one, C24H20BrN3O3
- The crystal structure of (Z)-3′-(2-(1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazinyl)-2′-hydroxy-[1,1′-biphenyl]-3-carboxylicacid ─ methanol (1/1), C26H26N4O5
- Crystal structure of (S)-1-phenylpropan-1-aminium (S)-(1-phenylpropyl)carbamate C19H26N2O2
- Synthesis and crystal structure of methyl 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate, C18H16BrN3O2S
- The crystal structure of trichlorobis(pyridine-2,6-dithio-κS-carbomethylamido)antimony(III), [SbCl3(C9H11N3S2)2]
- Crystal structure of 1,8-dihydroxy-3-{[(triphenylstannyl)oxy]carbonyl} anthracene-9,10-dione, C33H22O6Sn
- The crystal structure of (E)-4-(2-(pyridin-4-ylmethylene)hydrazine-1-carbonyl)pyridin-1-ium-2-olate dihydrate, C12H14N4O4
- The crystal structure of 6-amino-pyridinium-2-carboxylate, C6H6N2O2
- The crystal structure of catena-poly[aqua-nitrato-κ3O,O:O′′-(1,10-phenanthroline-κ2N,N′)sodium(I)], C24H18N6O7Na2
- Retractions
- Retraction of: Crystal structure of bis[diaquaisonicotinatosamarium(III)]-µ-isonicotinato-[diisonicotinatocopper(II)], CuSm2(C6H4NO2)8(H2O)4
- Retraction of: Crystal structure of aqua(2,2′-bipyridine-k 2 N:N′)(nitrato)-(4-aminobenzoato)cadmium(II) nitrate, [Cd(H2O)(NO3)(C10H8N2)(C7H7NO2)][NO3]